Crescent Grove Advisors, LLC Gilead Sciences, Inc. Transaction History

Crescent Grove Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$77.31 - $88.08 $18,399 - $20,963	-238 Reduced 3.92%	5,836 $484,000
Q4 2022 Jan 12, 2023	SELL	$62.32 - $89.47 $239,059 - $343,206	-3,836 Reduced 38.71%	6,074 $0
Q3 2022 Nov 08, 2022	BUY	$59.54 - $68.01 $590,041 - $673,979	9,910 New	9,910 $611,000
Q1 2022 May 04, 2022	SELL	$57.92 - $72.58 $242,105 - $303,384	-4,180 Closed	0 $0
Q4 2021 Jan 24, 2022	BUY	$64.88 - $73.64 $271,198 - $307,815	4,180 New	4,180 $303,000
Q3 2021 Oct 26, 2021	SELL	$67.69 - $73.03 $286,802 - $309,428	-4,237 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$63.47 - $69.35 $268,922 - $293,835	4,237 New	4,237 $292,000
Q1 2018 May 03, 2018	SELL	$72.84 - $88.8 $219,539 - $267,643	-3,014 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$72.11 - $85.47 $217,339 - $257,606	3,014	3,014 $244,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Crescent Grove Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Crescent Grove Advisors, LLC with notifications on news.